Major pathways of the reno-cardiovascular link: The sympathetic and renin-angiotensin systems

Kidney International Supplements

Volumn 1, Issue 1, 2011, Pages 13-16

  Blankestijn, Peter J ^a   London, Gerard ^b   Fliser, Danilo ^c   Jager, Kitty J ^d   Lindholm, Bengt ^e   Goldsmith, David ^f   Wiecek, Andrzej ^g   Suleymanlar, Gultekin ^h   Agarwal, Rajiv ⁱ   Ortiz, Alberto ^j   Massy, Ziad ^k,l   Martinez Castelao, Alberto ^m   Covic, Adrian ⁿ   Dekker, Friedo W ^o   Zoccali, Carmine ^p  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e KAROLINSKA INSTITUTE   (Sweden)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h AKDENIZ UNIVERSITY   (Turkey)

ⁱ INDIANA UNIVERSITY   (United States)

^j UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^k INSERM   (France)

^l AMIENS UNIVERSITY HOSPITAL   (France)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p CNR   (Italy)

more..

Author keywords

chronic kidney disease; hypertension; renin angiotensin; sympathetic activity

Indexed keywords

EID: 84884399850     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1038/kisup.2011.3     Document Type: Review

References (20)

1. Siddiqi L, Joles JA, Grassi G et al. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-1349.
2. Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 2000; 75: S2-S6. (Pubitemid 30205432)
3. Klein IH, Ligtenberg G, Neumann J et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14: 3239-3244. (Pubitemid 37509299)
4. Neumann J, Ligtenberg G, Klein IH et al. Response to sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49: 506-510.
5. Neumann J, Ligtenberg G, Klein II et al. Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65: 1568-1576. (Pubitemid 38591003)
6. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43: 699-706. (Pubitemid 38405571)
7. Mancia G, Grassi G, Giannattasio C et al. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34: 724-728. (Pubitemid 29501288)
8. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-46. (Pubitemid 34755977)
9. Siddiqi L, Prakken NH, Velthuis BK et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010; 25: 3272-3277.
10. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359. (Pubitemid 34260428)
11. Penne EL, Neumann J, Klein IH et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22: 208-215.
12. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328. (Pubitemid 29196594)
13. Neumann J, Ligtenberg G, Oey L et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004; 15: 2902-2907. (Pubitemid 41103399)
14. Klein IH, Ligtenberg G, Oey PL et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14: 425-430. (Pubitemid 36150866)
15. Hausberg M, Tokmak F, Pavenstadt H et al. Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease. J Hypertens 2010; 28: 1920-1927.
16. Cice G, Ferrara L, Di BA et al. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001; 37: 407-411.
17. Zilch O, Vos PF, Oey PL et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007; 25: 1285-1289. (Pubitemid 46918809)
18. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
19. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
20. Blankestijn PJ, Ritz E. Renal denervation: potential impact on hypertension in kidney disease? Nephrol Dial Transplant 2011 (in press).